Line 7: | Line 7: | ||
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=yes"> | <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=yes"> | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
<script> | <script> |
Revision as of 09:56, 8 October 2017
![](https://static.igem.org/mediawiki/2017/1/14/T--ETH_Zurich--Scroll.png)
Cancer kills over 8 million people every year. That's the entire population of Switzerland!
We need more specific therapies because current approaches result in many side-effects.
That's why we created CATE: Cancer-Targeting E. coli.
Learn more
We need more specific therapies because current approaches result in many side-effects.
That's why we created CATE: Cancer-Targeting E. coli.
Learn more
![](https://static.igem.org/mediawiki/2017/9/99/T--ETH_Zurich--CH.png)
![](https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png)
We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.
Project description
CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor
Design
![](https://static.igem.org/mediawiki/2017/8/8c/T--ETH_Zurich--ANDgate.png)
The high density of bacterial cells and the overproduction of lactate by the tumor together activate the first steps of CATE.
Design